Freedom Meditech’s mission is to transform the current standards of detection, diagnosis and monitoring for chronic disease, and thus, significantly improving the quality of life of individuals. We strive to incorporate high standards in our activities, with our employees, and the relationships we form. 


Freedom Meditech was incorporated in December 2006 and was founded with the goal of licensing, developing and commercializing non-invasive biophotonic technologies with clear market needs and overall global appeal. That same year the Company in-licensed non-invasive glucose monitoring technology from the University of Toledo.

In February 2009, the Company performed a product line acquisition from Guided Therapeutics, Inc. (OTCBB: GTHP). The acquisition included intellectual property, fully engineered prototypes and validation studies. 

The Company has been financed through angel and Series A and B venture capital funding.